Literature DB >> 20048748

Trichostatin A sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associated protein kinase.

Jun Wu1, Cheng-ping Hu, Qi-hua Gu, Ye-peng Li, Min Song.   

Abstract

AIM: To investigate the apoptosis-inducing effect of trichostatin A (TSA) in the human lung adenocarcinoma cisplatin-resistant cell line (A549/CDDP) and to examine whether TSA can enhance sensitivity to cisplatin treatment and the underlying molecular mechanisms of such an enhancement.
METHODS: Cell viability was evaluated using the Neutral Red assay. Apoptosis was assessed using Hoechst 33258 staining and flow cytometry analysis. Protein expression was detected by Western blotting. To determine the role of Death-associated protein kinase (DAPK) in TSA-induced apoptosis in the A549/CDDP cell line, cells were transfected with pcDNA3.1(+)-DAPK, which has a higher expression level of DAPK compared to endogenous expression, and DAPK activity was inhibited by both over-expression C-terminal fragment of DAPK which may competitive binding DAPK substrates to inhibit the function of DAPK and RNA interference.
RESULTS: TSA induced apoptosis in both A549 cells and A549/CDDP cells. TSA enhanced the sensitivity of A549/CDDP cells to cisplatin, along with concomitant DAPK up-regulation. When DAPK was over-expressed, A549/CDDP cells became sensitive to cisplatin and the cytotoxicity of TSA could be increased. Moreover, the cytotoxicity of TSA could be alleviated by inhibition of DAPK activity by the expression of a recombinant C-terminal fragment of DAPK or RNA interference.
CONCLUSION: TSA induced sensitivity to cisplatin treatment in cisplatin-resistant A549 cells. The up-regulation of DAPK is one of the mechanisms mediating sensitization to TSA-induced apoptosis in cisplatin-resistant cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20048748      PMCID: PMC4002697          DOI: 10.1038/aps.2009.183

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  37 in total

1.  A functional genetic screen identifies regions at the C-terminal tail and death-domain of death-associated protein kinase that are critical for its proapoptotic activity.

Authors:  T Raveh; H Berissi; M Eisenstein; T Spivak; A Kimchi
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

2.  Efflux of potassium ion is an important reason of HL-60 cells apoptosis induced by tachyplesin.

Authors:  Hai-tao Zhang; Jun Wu; Hai-feng Zhang; Qi-feng Zhu
Journal:  Acta Pharmacol Sin       Date:  2006-10       Impact factor: 6.150

3.  The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation.

Authors:  C Van Lint; S Emiliani; E Verdin
Journal:  Gene Expr       Date:  1996

4.  Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad.

Authors:  H Sawa; H Murakami; Y Ohshima; T Sugino; T Nakajyo; T Kisanuki; Y Tamura; A Satone; W Ide; I Hashimoto; H Kamada
Journal:  Brain Tumor Pathol       Date:  2001       Impact factor: 3.298

5.  Radio- and chemo-sensitization of human erythroleukemic K562 cells by the histone deacetylase inhibitor Trichostatin A.

Authors:  Tom C Karagiannis; Andrea J Smith; Assam El' Osta
Journal:  Hell J Nucl Med       Date:  2004 Sep-Dec       Impact factor: 1.102

Review 6.  The epigenomics of cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

7.  The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.

Authors:  Roberto R Rosato; Jorge A Almenara; Steven Grant
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

8.  Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells.

Authors:  Michela Muscolini; Roberta Cianfrocca; Angela Sajeva; Simona Mozzetti; Gabriella Ferrandina; Antonio Costanzo; Loretta Tuosto
Journal:  Mol Cancer Ther       Date:  2008-06       Impact factor: 6.261

Review 9.  Histone deacetylase inhibitors in cancer therapy.

Authors:  Min-Jung Lee; Yeong Sang Kim; Shivaani Kummar; Giuseppe Giaccone; Jane B Trepel
Journal:  Curr Opin Oncol       Date:  2008-11       Impact factor: 3.645

10.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

View more
  14 in total

1.  BnRCH gene inhibits cell growth of Hela cells through increasing the G2 phase of cell cycle.

Authors:  Qian Wan; Zhibin Liu; Wenzhen Peng; Jianmei Wang; Xufeng Li; Yi Yang
Journal:  Hum Cell       Date:  2011-10-30       Impact factor: 4.174

2.  The Topoisomerase 1 Inhibitor Austrobailignan-1 Isolated from Koelreuteria henryi Induces a G2/M-Phase Arrest and Cell Death Independently of p53 in Non-Small Cell Lung Cancer Cells.

Authors:  Chun-Chi Wu; Keh-Feng Huang; Tsung-Ying Yang; Ya-Ling Li; Chi-Luan Wen; Shih-Lan Hsu; Tzu-Hsiu Chen
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

3.  Effects of histone deacetylase inhibitor trichostatin A combined with cisplatin on apoptosis of A549 cell line.

Authors:  Xuan Zhang; Shu-Juan Jiang; Bin Shang; Hong-Juan Jiang
Journal:  Thorac Cancer       Date:  2015-03-02       Impact factor: 3.500

4.  Metformin inhibits the proliferation of A549/CDDP cells by activating p38 mitogen-activated protein kinase.

Authors:  Yajun Wang; Biyun Lin; Jun Wu; Haitao Zhang; Bin Wu
Journal:  Oncol Lett       Date:  2014-06-19       Impact factor: 2.967

5.  Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer.

Authors:  Frank P Vendetti; Michael Topper; Peng Huang; Irina Dobromilskaya; Hariharan Easwaran; John Wrangle; Stephen B Baylin; J T Poirier; Charles M Rudin
Journal:  Oncotarget       Date:  2015-01-01

6.  The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC.

Authors:  Yang Cai; Xiang Yan; Guoqing Zhang; Weihong Zhao; Shunchang Jiao
Journal:  Oncotarget       Date:  2015-08-07

7.  Scriptaid overcomes hypoxia-induced cisplatin resistance in both wild-type and mutant p53 lung cancer cells.

Authors:  Shrikant Pradhan; Divyank Mahajan; Prabhjot Kaur; Namita Pandey; Chandresh Sharma; Tapasya Srivastava
Journal:  Oncotarget       Date:  2016-11-01

8.  Dynamic Modeling of the Interaction Between Autophagy and Apoptosis in Mammalian Cells.

Authors:  I Tavassoly; J Parmar; A N Shajahan-Haq; R Clarke; W T Baumann; J J Tyson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-04-17

9.  Improving drug discovery with high-content phenotypic screens by systematic selection of reporter cell lines.

Authors:  Jungseog Kang; Chien-Hsiang Hsu; Qi Wu; Shanshan Liu; Adam D Coster; Bruce A Posner; Steven J Altschuler; Lani F Wu
Journal:  Nat Biotechnol       Date:  2015-12-14       Impact factor: 54.908

10.  Trichostatin A Enhances the Apoptotic Potential of Palladium Nanoparticles in Human Cervical Cancer Cells.

Authors:  Xi-Feng Zhang; Qi Yan; Wei Shen; Sangiliyandi Gurunathan
Journal:  Int J Mol Sci       Date:  2016-08-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.